.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Queensland Health
Julphar
Daiichi Sankyo
QuintilesIMS
Cipla
Moodys
McKesson
Boehringer Ingelheim
Argus Health

Generated: November 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,299,298

« Back to Dashboard

Which drugs does patent 8,299,298 protect, and when does it expire?


Patent 8,299,298 protects AURYXIA and is included in one NDA.

This patent has seventy-two patent family members in twenty countries.

Summary for Patent: 8,299,298

Title:Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
Abstract: The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
Inventor(s): Chan; Keith (Rockville, MD), Town; Winston (Hong Kong, CN)
Assignee: Globoasia, LLC (Rockville, MD)
Application Number:13/289,048
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Keryx Biopharms
AURYXIA
ferric citrate
TABLET;ORAL205874-001Sep 5, 2014RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,299,298

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,846,976Ferric organic compounds, uses thereof and methods of making same► Subscribe
7,767,851Ferric organic compounds, uses thereof and methods of making same► Subscribe
8,609,896Ferric organic compounds, uses thereof and methods of making same► Subscribe
9,328,133Ferric organic compounds, uses thereof and methods of making same► Subscribe
9,757,416Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same► Subscribe
8,754,258Ferric organic compounds, uses thereof and methods of making same► Subscribe
8,338,642Ferric organic compounds, uses thereof and methods of making same► Subscribe
8,901,349Ferric organic compounds, uses thereof and methods of making same► Subscribe
8,093,423Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same► Subscribe
8,754,257Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,299,298

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI375555► Subscribe
Taiwan200740431► Subscribe
TaiwanI335218► Subscribe
Taiwan200416027► Subscribe
Slovenia1601680► Subscribe
Portugal1601680► Subscribe
New Zealand566743► Subscribe
New Zealand541991► Subscribe
Malaysia162727► Subscribe
Mexico2008002360► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
US Army
Mallinckrodt
Teva
Boehringer Ingelheim
Baxter
Cipla
Fish and Richardson
McKesson
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot